US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

714.65

+9.131.29%

Number of Gainers:3

Number of Losers:1

Number of Flat:- -

PE:- -

High:723.01

Open:704.12

Low:696.33

Close:705.52

Volume:32.82M

Turnover:589.72M

Market Cap:22.49B

Float Cap:16.25B

Loading ...

Tempus AI management to meet virtually with BTIG

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Benzinga_recent_news

Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)

Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP)

Dyadic International, ERS Genomics announces CRISPR/Cas9 license

Crispr Therapeutics announces Phase 1 data for CTX310

Will Recursion’s (RXRX) CEO Transition and Roche Milestone Mark a Turning Point for Its AI Strategy?

Simply Wall St.

More Drugs to Fight High Cholesterol Are Emerging -- WSJ

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Tempus AI, Inc : H.c. Wainwright Cuts Target Price to $89 From $98

THOMSON REUTERS

Recursion Pharmaceuticals CEO Christopher Gibson Reports Disposal of Common Shares

Rallybio posts Q3 net income of $16 million

TD Cowen Remains a Hold on Tempus AI, Inc. Class A (TEM)

Recursion Pharmaceuticals: Q3 2025 Financial Highlights

Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says

Benzinga_recent_news

Tempus AI Unveils Six New Immunotherapy Research Presentations at SITC 2025

Recursion Pharmaceuticals Announces New CEO Appointment

Recursion Pharmaceuticals Shares 5.4% Premarket After Q3 Revenue Miss

THOMSON REUTERS

Recursion Q3 revenue misses estimates, net loss widens

Tempus AI Shares Down 4% Premarket After Co Reports Q3 Loss

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":714.6468,"timestamp":1762894799999,"preClose":705.51855,"halted":0,"volume":32824074,"delay":0,"changeRate":0.012938,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":9.128235,"latestTime":"11-11 16:00:00 EST","open":704.11505,"high":723.0067,"low":696.3285,"amount":589716168.562202,"amplitude":0.037814,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1762957800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.307137,"peRate":-12.324284,"turnoverRate":0.047083,"increases":3,"decrements":1,"flats":0,"marketCap":22485800960,"floatMarketCap":16251317632},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":723.0067,"amplitude":0.037814,"preClose":705.51855,"low":696.3285,"pbRate":"5.307137","latestPrice":714.6468,"volume":32824074,"delay":0,"open":704.11505,"prevYearClose":530.4984,"prevWeekClose":711.2595,"prevMonthClose":855.6119,"prevQuarterClose":803.2486,"fiveDayClose":783.1412,"twentyDayClose":885.1539,"sixtyDayClose":746.2554,"secType":"PLATE","market":"US","turnoverRate":0.047083,"peRate":-12.324284,"marketCap":22485800960,"floatMarketCap":16251317632,"timestamp":1762894799999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":3,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582392615","title":"Tempus AI management to meet virtually with BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2582392615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582392615?lang=en_us&edition=fundamental","pubTime":"2025-11-12 04:05","pubTimestamp":1762891517,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on November 18 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-management-to-meet-virtually-with-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-management-to-meet-virtually-with-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TEM","BK4611","BK4121","LU1861558580.USD","LU1861559042.SGD","BK4613"],"gpt_icon":0},{"id":"2582046360","title":"CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2582046360","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582046360?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:50","pubTimestamp":1762872600,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48779688/crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48779688/crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["USJW.SI","PSQ","TQQQ","MNQmain","LU1917777945.USD","LU1861558580.USD","LU1861559042.SGD","LU0320765992.SGD","NVIW.SI","LU2362540622.SGD","SQQQ","TSYW.SI","TG","BK4588","LU2468319806.SGD","LU0053666078.USD","CRSP","LU0823434740.USD","BK4556","LU0823434583.USD","BK4090","LU2023250504.SGD","LU2089984988.USD",".IXIC","BK4153","USAW.SI","LU2362541273.HKD","BK4585","LU1974910355.USD","ARWR","LU0058720904.USD","LU0823416689.USD","QID","LU0109394709.USD","LU0882574055.USD","QLD","LU2106854487.HKD","NQmain","LU2362541513.USD","BK4611","LU0114720955.EUR","LDL","LU0289739699.SGD","BK4139","LU0889565916.HKD","REGN","LU2237438978.USD"],"gpt_icon":1},{"id":"2582518533","title":"Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582518533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582518533?lang=en_us&edition=fundamental","pubTime":"2025-11-11 16:58","pubTimestamp":1762851500,"startTime":"0","endTime":"0","summary":"Barclays analyst Gena Wang maintained a Hold rating on Crispr Therapeutics AG today and set a price target of $56.00. According to TipRanks, Wang i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-crispr-therapeutics-ag-crsp-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-crispr-therapeutics-ag-crsp-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRSP","BK4139","BK4611","BK4556","BK4585","LU1861558580.USD","BK4588","BK4210","LU1861559042.SGD","AG"],"gpt_icon":0},{"id":"2582087198","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582087198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582087198?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:10","pubTimestamp":1762780226,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on AMN Healthcare Services (AMN – Research Report) and Crispr Therap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amn-healthcare-services-amn-and-crispr-therapeutics-ag-crsp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amn-healthcare-services-amn-and-crispr-therapeutics-ag-crsp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4210","BK4139","LABU","BK4556","AMN","BK4581","BK4588","XLV","CRSP","AG","LU1861559042.SGD","LU1861558580.USD","BK4585","BK4196","BK4611","HCAR"],"gpt_icon":0},{"id":"2582876132","title":"Dyadic International, ERS Genomics announces CRISPR/Cas9 license","url":"https://stock-news.laohu8.com/highlight/detail?id=2582876132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582876132?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:38","pubTimestamp":1762778286,"startTime":"0","endTime":"0","summary":"ERS Genomics and Dyadic International (DYAI) announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 pat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyadic-international-ers-genomics-announces-crispr-cas9-license-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyadic-international-ers-genomics-announces-crispr-cas9-license-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","LU1861558580.USD","LU1861559042.SGD","DYAI","BK4611","CRSP","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2582818494","title":"Crispr Therapeutics announces Phase 1 data for CTX310","url":"https://stock-news.laohu8.com/highlight/detail?id=2582818494","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582818494?lang=en_us&edition=fundamental","pubTime":"2025-11-10 02:10","pubTimestamp":1762711808,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (CRSP) announced positive Phase 1 data from its ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-announces-phase-1-data-for-ctx310-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-announces-phase-1-data-for-ctx310-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","BK4588","BK4585","LU1861558580.USD","CRSP","BK4611","BK4556","BK4139"],"gpt_icon":0},{"id":"2582989511","title":"Will Recursion’s (RXRX) CEO Transition and Roche Milestone Mark a Turning Point for Its AI Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2582989511","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582989511?lang=en_us&edition=fundamental","pubTime":"2025-11-09 12:40","pubTimestamp":1762663255,"startTime":"0","endTime":"0","summary":"Earlier this month, Recursion Pharmaceuticals announced the upcoming appointment of Najat Khan, Ph.D., as CEO and President effective January 1, 2026, and received a US$30 million milestone payment from Roche and Genentech for delivering a whole-genome phenotypic map of microglial immune cells.\nKhan’s leadership background in scaling AI capabilities in drug discovery, along with the milestone payment, highlights Recursion’s ongoing focus on AI-driven collaborations and R&D momentum.\nWe'll...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/will-recursions-rxrx-ceo-transition-and-roche-milestone-mark","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/will-recursions-rxrx-ceo-transition-and-roche-milestone-mark","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AI","BK4539","RXRX","BK4548","TPB","BK4609","BK4587","BK4023","BK4528","BK4551","BK4139","BK4611","BK4075","BK4543","BK4588","BK4585"],"gpt_icon":1},{"id":"2582509862","title":"More Drugs to Fight High Cholesterol Are Emerging -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2582509862","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582509862?lang=en_us&edition=fundamental","pubTime":"2025-11-09 06:28","pubTimestamp":1762640880,"startTime":"0","endTime":"0","summary":"A statin isn't the only answer anymore to lowering cholesterol.The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades. But they don't work for everyone, and can only reduce harmful \"bad\" cholesterol so much.Now some patients have other cholesterol-busting medicines available as options -- and even more alternatives are on the horizon.Certain patients already can take a twice-yearly injection, sold by Novartis as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body's ability to clear the bad form of cholesterol.Biotech Amgen has been doing testing to expand use of its PCSK9 drug Repatha to more patients, while Merck is developing an easier-to-take pill version. Biotechs are working on therapies that use gene-editing technology to lower people's cholesterol, perhaps permanently.High cholesterol is a majo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","LU1061106388.HKD","LU1093756325.SGD","LU1934455863.HKD","LU1037948541.HKD","LU2324357040.USD","CRSP","NTLA","LU2361045086.USD","BK4534","LU2461242641.AUD","LU1116320737.USD","NVS","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1929549753.HKD","SG9999013999.USD","LU1037948897.HKD","LU1989771016.USD","LU0861579265.USD","LU1989772923.USD","BK4533","LU1699723380.USD","BK4556","AMGN","LU2023250843.SGD","SG9999002232.USD","SG9999014542.SGD","IE00B4R5TH58.HKD","BK4581","IE00BSNM7G36.USD","LU1934455277.USD","MRK","BK4611","LU0211331839.USD","BK4139","LU0234572021.USD","SG9999014559.SGD","LU1861559042.SGD","LU2242646821.SGD","LU1941712348.USD","BK4007","LU0058720904.USD","LU0098860793.USD","LU1989772840.SGD","SG9999001440.SGD","LU1093756168.USD","LU0070302665.USD","LU1035773651.USD","BK4585"],"gpt_icon":0},{"id":"2582862650","title":"Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema","url":"https://stock-news.laohu8.com/highlight/detail?id=2582862650","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582862650?lang=en_us&edition=fundamental","pubTime":"2025-11-09 06:13","pubTimestamp":1762639980,"startTime":"0","endTime":"0","summary":"Deep, stable and durable reductions in kallikrein observedAmong 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 (7","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/08/3184092/0/en/Intellia-Therapeutics-Presents-Positive-Pooled-Phase-1-2-Data-of-Lonvoguran-Ziclumeran-lonvo-z-in-Patients-with-Hereditary-Angioedema.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","HAE","BK4611","LU1861558580.USD","IE0034390439.USD","LU0012050646.USD","NTLA","BK4198","LU1861559042.SGD","IE00B64QTZ34.USD","LU1169589451.USD","IE0009354923.USD","BK4535","BK4588","LU1169590202.USD","CRSP","BK4183","LU0205193047.USD","ODD","BK4585","IE00B19Z6F94.USD","LU0205194284.USD","BK4139","LU0106261612.USD","IE00BLDYK493.USD"],"gpt_icon":0},{"id":"2581001603","title":"Tempus AI, Inc : H.c. Wainwright Cuts Target Price to $89 From $98","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001603?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:18","pubTimestamp":1762514314,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ea115fe808cfcb277a4d399278b789a8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nAZN4QLSFQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4613","LU1861559042.SGD","LU1861558580.USD","TEM","BK4611"],"gpt_icon":0},{"id":"2581043813","title":"Recursion Pharmaceuticals CEO Christopher Gibson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581043813","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581043813?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:27","pubTimestamp":1762464445,"startTime":"0","endTime":"0","summary":"Christopher Gibson, Chief Executive Officer and Director of Recursion Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL8HCSBK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Pharmaceuticals CEO Christopher Gibson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4539","BK4609","BK4139","RXRX","BK4548"],"gpt_icon":1},{"id":"2581509362","title":"Rallybio posts Q3 net income of $16 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581509362","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581509362?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:03","pubTimestamp":1762434223,"startTime":"0","endTime":"0","summary":"Rallybio Corporation reported a net income of $16.0 million, or $0.36 per common share, for the third quarter of 2025, compared to a net loss of $11.5 million, or $0.26 per common share, for the same period in 2024. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $59.3 million. During the quarter, Rallybio generated $20.0 million from the sale of its interest in REV102 to Recursion Pharmaceuticals. The company advanced its lead program, RLYB116, with the completion of dosing in Cohort 1 of its confirmatory Phase 1 study, and expects to report data from the second cohort in the fourth quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content us","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL807x3b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","RLYB","BK4139","BK4539","BK4609","BK4548"],"gpt_icon":1},{"id":"2581037124","title":"TD Cowen Remains a Hold on Tempus AI, Inc. Class A (TEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581037124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581037124?lang=en_us&edition=fundamental","pubTime":"2025-11-06 13:55","pubTimestamp":1762408530,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Tempus AI, Inc. Class A, with a price target of $88.00. Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-hold-on-tempus-ai-inc-class-a-tem-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-hold-on-tempus-ai-inc-class-a-tem-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4613","BK4207","BK4127","TEM","COWN","BK4543","BK4587","AI","BK4121","TD","BK4611","BK4588","BK4023","BK4528","LU1861558580.USD","LU1861559042.SGD","BK4551","BK4585","BK4566"],"gpt_icon":0},{"id":"2581031019","title":"Recursion Pharmaceuticals: Q3 2025 Financial Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2581031019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581031019?lang=en_us&edition=fundamental","pubTime":"2025-11-06 13:13","pubTimestamp":1762406003,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals, Inc ( ($RXRX) ) has released its Q3 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc pres...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-q3-2025-financial-highlights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-q3-2025-financial-highlights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4609","RXRX","BK4548","BK4539","BK4611","BK4139"],"gpt_icon":0},{"id":"2581081437","title":"Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2581081437","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581081437?lang=en_us&edition=fundamental","pubTime":"2025-11-06 02:00","pubTimestamp":1762365600,"startTime":"0","endTime":"0","summary":"Tempus AI beats Q3 revenue estimates with $334.21M, narrows adjusted loss to $0.11 per share, and raises FY25 guidance to $1.265B.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/05/Tempus-AI-FDA-Approval--Ark-Move.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/05/Tempus-AI-FDA-Approval--Ark-Move.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/11/48663472/tempus-ai-growth-outlook-boosted-by-higher-asps-pharma-contracts-analyst-says","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/11/48663472/tempus-ai-growth-outlook-boosted-by-higher-asps-pharma-contracts-analyst-says","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1861558580.USD","LU1861559042.SGD","BK4611","BK4121","TEM","BK4613"],"gpt_icon":1},{"id":"2581778670","title":"Tempus AI Unveils Six New Immunotherapy Research Presentations at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581778670","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581778670?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:31","pubTimestamp":1762349477,"startTime":"0","endTime":"0","summary":"Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming Society for Immunotherapy of Cancer  Annual Meeting 2025, scheduled to take place from November 5 to 9 at the Gaylord National Convention Center in National Harbor, Maryland. The company will present new scientific and clinical research findings through six poster presentations. Among the studies to be presented is a novel multi-omic algorithm developed to predict real-world outcomes in patients with rare, advanced solid cancers treated with off-label immune checkpoint inhibitors. Another study will highlight the TargetR computational framework, which integrates pharmacologic, genomic, transcriptomic, and proteomic data to support the discovery and validation of immunotherapy targets. Additionally, Tempus will share exploratory data on its Immune Profile Score , a DNA- and RNA-based molecular signature, as a potential predictive biomarker for benefit from immune checkpoint inhibitors in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL1sYG3f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4613","BK4121","LU1861559042.SGD","BK4611","LU1861558580.USD"],"gpt_icon":1},{"id":"2581729215","title":"Recursion Pharmaceuticals Announces New CEO Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2581729215","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581729215?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:58","pubTimestamp":1762343926,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-announces-new-ceo-appointment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-announces-new-ceo-appointment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","RXRX","BK4139","BK4539","BK4609","BK4548"],"gpt_icon":0},{"id":"2581726489","title":"Recursion Pharmaceuticals Shares 5.4% Premarket After Q3 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2581726489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581726489?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:40","pubTimestamp":1762342831,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e0b11eb1759d2fa3a59526eca8ac097c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL4N3WH11P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","RXRX","BK4539","BK4139","BK4609","BK4548"],"gpt_icon":0},{"id":"2581266227","title":"Recursion Q3 revenue misses estimates, net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581266227","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581266227?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:39","pubTimestamp":1762342770,"startTime":"0","endTime":"0","summary":"Recursion Q3 revenue misses estimates, net loss widensOverviewRecursion Q3 operating revenue misses analyst expectationsNet loss for Q3 widens, missing analyst estimatesAchieved $30 mln milestone from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e0b11eb1759d2fa3a59526eca8ac097c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0IP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4609","BK4611","BK4139","BK4548","RXRX"],"gpt_icon":1},{"id":"2581726820","title":"Tempus AI Shares Down 4% Premarket After Co Reports Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2581726820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581726820?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:32","pubTimestamp":1762342322,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"2209e55743da64a925568f118f48e03f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL4N3WH118:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TEM","BK4611","LU1861558580.USD","BK4613","BK4121","LU1861559042.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}]}}